ArticleAnnals of surgical oncology2026
Association of Cancer Center Designation with Multimodality Treatment, Perioperative Outcomes, and Survival among Older Adults with Pancreatic Ductal Adenocarcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Borderline Resectability in Perihilar Cholangiocarcinoma - Anatomic and Biologic Considerations.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer center designation may influence treatment patterns and outcomes for patients with pancreatic ductal adenocarcinoma (PDAC); comparative data across non-designated (ND), Commission on Cancer/American College of Surgeons (CoC/ACS), and National Cancer Institute (NCI)-designated centers remain limited. We evaluated associations between designation, multimodality treatment, perioperative outcomes, and survival in stage I-III PDAC. PATIENTS AND
methodsThe analytic cohort consisted of patients with stage I-III PDAC in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2005-2019), while patients with stage IV disease were assessed using descriptive comparisons. Multivariable models were utilized to assess associations between center designation and outcomes of interest.
resultsAmong 12,971 patients, median age was 76 years (IQR 71-81 years), and 54.6% (n = 7083) were female. Most patients received care at non-NCI CoC (42.0%, n = 5446) or NCI-designated centers (39.8%, n = 5,164). Nurse-to-bed ratios were higher at NCI-designated centers (1.61, IQR 1.25-2.22) and non-NCI CoC centers (1.19, IQR 0.91-1.52) compared with ND centers (0.93, IQR 0.60-1.30) (p < 0.001). Multimodality treatment within 180 days post-surgery was more common at NCI centers (56.2%, n = 1327) versus non-NCI CoC (34.2%, n = 1861) and ND centers (33.4%, n = 1725). In adjusted analyses, care at NCI-designated centers was associated with higher odds of undergoing surgical resection (aOR 2.37, 95% CI 2.12-2.65) and lower 1-year mortality hazard (aHR 0.50, 95% CI 0.46-0.54) compared with ND centers.
conclusionsCompared with non-designated centers, care at NCI-designated centers was associated with greater use of multimodality therapy and improved survival among patients with stage I-III PDAC, whereas non-NCI CoC centers demonstrated outcomes that were generally closer to non-designated centers than to NCI-designated centers. These findings highlight the importance of access to centers delivering coordinated multimodality PDAC care.
Identifiers
42560641What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.